Cargando…
Healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy
OBJECTIVES: Our primary aim was to evaluate the healthcare resource use associated with the diagnosis of transthyretin amyloidosis cardiomyopathy. Second, we aim to assess the effect of the number of diagnostic tests and clinical contact points on the total time and costs between symptom onset and d...
Autores principales: | Asher, Clint, Guilder, Andrew, Finocchiaro, Gherardo, Carr‐White, Gerry, Rodríguez‐Guadarrama, Yael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733838/ https://www.ncbi.nlm.nih.gov/pubmed/35024457 http://dx.doi.org/10.1002/hsr2.466 |
Ejemplares similares
-
Diagnosis and treatment of transthyretin‐related amyloidosis cardiomyopathy
por: Teng, Catherine, et al.
Publicado: (2020) -
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022) -
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022) -
Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021) -
A Late Diagnosis of Transthyretin Amyloidosis
por: Pfirman, Kristopher S, et al.
Publicado: (2022)